Development & Characterization of IBI3055, a 2+1 Format, CD19 & BCMA Dual Targeting T-Cell Engager for Autoimmune Diseases

• Novel T-cell engager for autoimmune diseases
• CD19 and BCMA targeting therapies for B-cell and plasma cell depletion
• New therapeutic approaches for drug for immune resetting

Speakers:

Jinyang Li

Associate Director

Innovent Biologics